azithromycin - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.43 [0.13, 1.44]< 10%1 study (1/-)91.5 %some concernnot evaluable moderatecrucial-
clinical improvement 0.82 [0.47, 1.43]> 10%1 study (1/-)24.2 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 0.82 [0.47, 1.43]> 10%1 study (1/-)24.2 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.89 [0.59, 1.35]> 10%1 study (1/-)29.3 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.64 [0.94, 2.88]> 10%1 study (1/-)95.8 %some concernnot evaluable moderateimportant-
ventilation 1.54 [0.70, 3.37]< 10%1 study (1/-)14.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.02 [0.20, 5.10]< 10%1 study (1/-)49.1 %some concernnot evaluable moderateimportant-
adverse events 1.21 [0.82, 1.78]< 10%1 study (1/-)17.4 %some concernnot evaluable moderatenon important-
renal impairment 1.35 [0.47, 3.86]< 10%1 study (1/-)28.8 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.